{"entity":{"id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","aka":[],"tldr":"Lipegfilgrastim (Lonquex) is a once-per-chemotherapy-cycle white cell booster used in Europe, similar to pegfilgrastim, for adults and children from two years old.","summary":"Lipegfilgrastim was authorised by the European Commission in July 2013 for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy (excluding CML and MDS), extended to children aged 2 and over in 2021, on phase 3 trials in breast cancer (non-inferior duration of severe neutropenia versus pegfilgrastim) and NSCLC (superior to placebo). It differs from pegfilgrastim in the site-specific enzymatic glycopegylation used to attach the polyethylene glycol chain. It is not approved in the US. Bone pain and musculoskeletal pain are the common adverse effects; splenic rupture and pulmonary adverse reactions are rare class risks. Marketed by Teva.","status":"approved","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/Lipegfilgrastim","links":[{"label":"XM22-03 (BMC Cancer 2013)","url":"https://doi.org/10.1186/1471-2407-13-386"},{"label":"EPAR (EMA)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex"}],"tags":["ema-list","supportive"],"related":["pegfilgrastim"],"cancers":[],"sections":[],"technologies":["g-csf-growth-factors"],"targets":[],"drugs":[],"companies":["teva"],"institutions":[],"pathways":[],"terms":[],"trials":["xm22-03"],"people":[],"bottlenecks":[],"keyPapers":["paper-xm22-03-bondarenko-bmc-cancer-2013"],"journals":[],"dependsOn":[],"notes":[],"brand":"Lonquex","modality":"Glycopegylated recombinant G-CSF","supportive":true,"mechanism":"Filgrastim site-specifically glycopegylated at threonine 134; reduced renal clearance gives once-per-cycle dosing with neutrophil-mediated self-regulating elimination.","approvals":[{"region":"EU","year":2013,"indication":"Reduction in duration of neutropenia and febrile neutropenia after cytotoxic chemotherapy in adults (children from 2 years added 2021)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lipegfilgrastim/","neighbours":{"drug":[{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/"}],"technology":[{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/"}],"company":[{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","route":"/companies/teva/"}],"trial":[{"id":"xm22-03","kind":"trial","name":"XM22-03","route":"/trials/xm22-03/"}],"paper":[{"id":"paper-xm22-03-bondarenko-bmc-cancer-2013","kind":"paper","name":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)","route":"/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/"}]}}